<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934840</url>
  </required_header>
  <id_info>
    <org_study_id>2018LS158</org_study_id>
    <nct_id>NCT03934840</nct_id>
  </id_info>
  <brief_title>CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone</brief_title>
  <official_title>A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II clinical trial in patients with metastatic castration sensitive prostate&#xD;
      cancer. The objective of the study is to determine the efficacy and further define the safety&#xD;
      of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with&#xD;
      cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin&#xD;
      and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone&#xD;
      with ADT. The primary objective is to determine the percent of subjects that have no PSA or&#xD;
      radiographic progression at 1 year. Secondary objectives will include determining the&#xD;
      progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and&#xD;
      cabazitaxel in combination with ADT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-Specific Antigen (PSA) or Radiographic Progression</measure>
    <time_frame>1 Year</time_frame>
    <description>Proportion of patients who have no PSA or radiographic progression as determined by RECIST 1.1 or PCWG3 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Nadir</measure>
    <time_frame>1 Year</time_frame>
    <description>Time to time to PSA nadir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>1 Year</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Homologous Recombination Deficiency (HRD)</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of HRD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Complete Response Rate</measure>
    <time_frame>1 Year</time_frame>
    <description>PSA complete response rate (PSA &lt;0.2 ng/ml) in patient with mutations in DNA repair genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Complete Response Rate</measure>
    <time_frame>1 Year</time_frame>
    <description>PSA complete response rate (PSA &lt;0.2 ng/ml) in patient without mutations in DNA repair genes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Progression</measure>
    <time_frame>1 Year</time_frame>
    <description>Time to PSA progression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin, Cabazitaxel and Abiraterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>20 mg/m2 Q 21 days</description>
    <arm_group_label>Carboplatin, Cabazitaxel and Abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 4 Q21 Days x 6 cycles with ADT</description>
    <arm_group_label>Carboplatin, Cabazitaxel and Abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>1000 mg PO daily</description>
    <arm_group_label>Carboplatin, Cabazitaxel and Abiraterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg PO daily on chemotherapy completion</description>
    <arm_group_label>Carboplatin, Cabazitaxel and Abiraterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide, or have a legally authorized representative provide,&#xD;
             written informed consent and HIPAA authorization for the release of personal health&#xD;
             information. A signed informed consent must be obtained before screening procedures&#xD;
             are performed.&#xD;
&#xD;
          -  Histologically confirmed prostate cancer.&#xD;
&#xD;
          -  High volume metastatic disease (defined as the presence of visceral metastases or ≥3&#xD;
             bone lesions).&#xD;
&#xD;
          -  ADT for ≤3 months by day 1 of study chemotherapy; Prior episodes of ADT are allowed&#xD;
             (i.e. ADT used previously in courses of radiation).&#xD;
&#xD;
          -  Testosterone &lt;50 ng/dL. Patients must continue primary ADT with an LHRH analogue if&#xD;
             they have not undergone orchiectomy.&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1 (see Appendix A)&#xD;
&#xD;
          -  Patient has adequate bone marrow and organ function as defined by the following&#xD;
             laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 × 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 × 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dl&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5mg/dL or estimated creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
               -  In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate&#xD;
                  aminotransferase (AST) &lt;2.5 x ULN. If the patient has liver metastases, ALT and&#xD;
                  AST &lt;5 x ULN&#xD;
&#xD;
               -  Total bilirubin &lt; ULN; or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x&#xD;
                  ULN in patients with well-documented Gilbert's Syndrome.&#xD;
&#xD;
          -  Sexually active males must use a condom during intercourse while taking study drugs&#xD;
             and for 30 days after stopping treatment and should not father a child in this period.&#xD;
             A condom is required to be used also by vasectomized men in order to prevent delivery&#xD;
             of the drug via seminal fluid. Fertile males must use a condom with spermicide (double&#xD;
             barrier method).&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to any chemotherapy, PARPi, or immunotherapy for prostate cancer.&#xD;
&#xD;
          -  Prior abiraterone or enzalutamide, unless therapy was for &lt; 2 weeks&#xD;
&#xD;
          -  Radiation therapy (including palliative radiotherapy to a metastatic lesion) within 14&#xD;
             days or major surgery (e.g., open abdominal, pelvic, thoracic, orthopedic or&#xD;
             neurosurgery) within 28 days of the date of the first dose.&#xD;
&#xD;
          -  Other systemic therapies for prostate cancer within 28 days or 5 half-lives, whichever&#xD;
             is shorter, prior to day 1 of chemotherapy (with the exception of anti-androgens like&#xD;
             bicalutamide).&#xD;
&#xD;
          -  PSA &lt;2.0 ng/mL at diagnosis.&#xD;
&#xD;
          -  If present, peripheral neuropathy must be ≤ Grade 1&#xD;
&#xD;
          -  Patients with an active second malignancy that could, in the investigator's opinion,&#xD;
             potentially interfere with the patient's ability to participate and/or complete this&#xD;
             trial.&#xD;
&#xD;
          -  Patients with central nervous system (CNS) involvement unless they meet ALL of the&#xD;
             following criteria:&#xD;
&#xD;
               -  At least 4 weeks from prior therapy completion (including radiation and/or&#xD;
                  surgery) prior to starting the study treatment&#xD;
&#xD;
               -  Clinically stable CNS tumor at the time of screening.&#xD;
&#xD;
               -  Baseline screening for CNS metastases is not required unless presence of signs&#xD;
                  and/or symptoms of involvement&#xD;
&#xD;
          -  Patients with severe psychiatric illness/social situations that would limit compliance&#xD;
             with study requirements in the judgment of treating investigator.&#xD;
&#xD;
          -  Patient has a history of non-compliance to medical regimen or inability to grant&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Ryan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Hematology, Oncology and Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamy Grainger</last_name>
    <phone>612 273 2800</phone>
    <email>tgraing1@fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Ryan, MD</last_name>
    <phone>6126249487</phone>
    <email>ryanc@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan Bryce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David VanderWeele, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Stadler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro C Barata, MD.MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamy Grainger</last_name>
      <phone>612-273-2800</phone>
      <email>tgraing1@fairview.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicholas J Vogelzang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jeferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Kevin Kelly, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifespan Cancer Institute</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andre De Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

